Mazdutide

Mazdutide (IBI362)

Evidence & Status

  • Strong Human Evidence
  • Strong

At a Glance

A modified 34-amino-acid dual GLP-1/glucagon receptor agonist with China-specific approvals and direct Phase 3 evidence.

Plain English

Mazdutide is not FDA-approved in the United States; the listed approvals are China-specific.

Overview

A modified 34-amino-acid dual GLP-1/glucagon receptor agonist. China-specific NMPA approvals cover chronic weight management in specified adults with overweight or obesity and glycemic control in adults with type 2 diabetes.

Research Summary

Direct Phase 3 evidence includes Chinese adult obesity/overweight and type 2 diabetes studies. Trial exposures and administration are study-specific and are not universal dosing recommendations.

Research Areas

  • Type 2 diabetes
  • Obesity and weight management
  • Non-alcoholic fatty liver disease (NAFLD/NASH)
  • Metabolic syndrome
  • Dual incretin pharmacology

Safety & Risks

Serious Risks

  • Potential thyroid C-cell effects (GLP-1 class risk; not confirmed in humans)
  • Pancreatitis (GLP-1 class risk)
  • Not available outside clinical trials
  • Safety profile still under evaluation

Reported Side Effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Decreased appetite
  • Injection site reactions
United States
Not FDA-approved in the United States. China-specific NMPA approvals: chronic weight management in specified adults with overweight or obesity (June 2025), and glycemic control in adults with type 2 diabetes (September 2025).
United Kingdom
Investigational only
Australia
Investigational only
Canada
Investigational only

Citations & Sources